Lung Cancers Today

?? Ivonescimab significantly improved PFS compared with pembrolizumab in patients with previously untreated advanced PD-L1–positive NSCLC, according to HARMONi-2 results published today in The Lancet Group. ?? Learn more: https://buff.ly/Kn61kC7 #lcsm #LungCancer #NSCLC

?? Can systematic immune inflammation predict survival outcomes in patients receiving immune checkpoint inhibitors for NSCLC? ?? A recent study provided key insights on using a pretreatment systematic immune inflammation index in this setting. ?? Read more: https://buff.ly/Yvva73h #lcsm #NSCLC

?? A recent report by a team from Vanderbilt University's Ingram Cancer Center documents “the first reported case of a RET fusion as a potential mechanism of resistance to lorlatinib." ?? Learn more: https://buff.ly/3QHi55P #NSCLC #lcsm #LungCancer

?? Do characteristics and treatment responses differ between patients with KRAS G12C and G12D NSCLC? ?? A recent real-world study by Adel Shahnam of Peter MacCallum Cancer Centre and colleagues provided key insights. ?? Learn more: https://buff.ly/3Xk8hT5 #NSCLC

?? The FDA has granted Fast Track Designation to IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, for certain patients with squamous NSCLC, according to an announcement from Innovent Biologics, Inc. ?? Learn more: https://lnkd.in/g3BQ5kkv #NSCLC #lcsm

?? What are the critical considerations surrounding sublobar resection for patients with early-stage NSCLC? ??? In this interview, Robert Merritt, MD, MBA, FACS, of Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute, shares key insights from his systematic review on the topic. ?? Watch: https://lnkd.in/gnFgsgRS #lcsm #lungcancer #NSCLC #surgery

?? The FDA has granted Priority Review to the New Drug Application for zongertinib (BI 1810631) as a treatment for adults with unresectable or metastatic NSCLC whose tumors have?HER2 mutations and who have received prior systemic therapy, according to an announcement from Boehringer Ingelheim. ?? Learn more: https://lnkd.in/gbUhqQjA #NSCLC #lcsm

??? Don't miss our new interview with Dr. Stephen Liu of Georgetown University Lombardi Comprehensive Cancer Center, who joined us to share key insights on the phase 2 eNRGy trial, NRG1 fusions in NSCLC, and the recent approval of zenocutuzumab. ?? Watch now: https://lnkd.in/gH685QSR #NSCLC #lcsm

?? CheckMate-816 showed a “statistically significant and clinically meaningful improvement” in OS with the addition of nivolumab to platinum-doublet chemotherapy as a neoadjuvant treatment for resectable NSCLC, according to an announcement today from Bristol Myers Squibb. ?? Read more: https://buff.ly/3X45rS4 #lcsm #NSCLC

?? ICYMI: The Lung Cancer Research Foundation has announced its latest scientific grant program awards will fund $3.55 million in new research, marking “the largest single-year investment in its history.” ?? Learn more about the research that will be funded: https://lnkd.in/gitRVVRp #lcsm #LungCancer #awards #grants